XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label ...

Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY™ ...

Physician-scientists from Rutgers Cancer Institute and RWJBarnabas Health will share new discoveries from their basic science ...

KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

Ahead of the upcoming American Society of Hematology (ASH) annual meeting, Alex Niu, MD, of Roswell Park Comprehensive Cancer ...

Zynlonta and glofitamab show high response and durable remission rates in early r/r DLBCL trial data from ADC Therapeutics, ...

Tattoo ink doesn’t just sit inertly in the skin. New research shows it moves rapidly into the lymphatic system, where it can ...

Mouse research shows tattoo pigments move into lymph nodes within minutes and persist for months Ink triggered immune-cell ...

Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is indicated for the treatment of adult and paediatric patients 12 years and older with unresectable or metastatic microsatellite ...

Bristol Myers Squibb BMY obtained the European Commission’s (“EC”) approval for a label expansion of Breyanzi (lisocabtagene ...